FIELD: chemistry.
SUBSTANCE: invention concerns novel compounds in the form of peptide agonists of vasopressin receptor V1a, of the general formula (I) 
, and treatment method for shock of hypovolemic or vasodilation origin, esophagus vein dilation with hemorrhage, hepatorenal syndrome, cardiopulmonary resuscitation, anesthesia-induced hypotension, orthostatic hypotension, blood circulation malfunction induced by paracentesis, blood loss during operation or in connection with burn treatment, or nosebleeding. Additionally invention concerns pharmaceutical compositions including claimed compounds as active component in therapeutically effective quantity, and application of claimed compounds in medicine manufacturing.
EFFECT: obtaining compounds with agonistic effect on vasopressin receptor V1a.
12 cl, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE COMPOUNDS | 2007 |
|
RU2415149C2 |
| V1A-RECEPTORS AGONISTS | 2013 |
|
RU2634617C2 |
| OXYTOCIN ANALOGUES | 2009 |
|
RU2496788C2 |
| SYNTHETIC PEPTIDE AMIDES AND THEIR DIMERS | 2007 |
|
RU2510399C2 |
| PEPTIDE VECTORS | 2004 |
|
RU2361876C2 |
| SYNTHETIC PEPTIDE AMIDES | 2007 |
|
RU2500685C2 |
| NEW OCTAPEPTIDE COMPOUNDS REPRESENTING SOMATOSTATIN DERIVATIVES | 2009 |
|
RU2547940C2 |
| GLP-1 ANALOGUE DERIVATIVE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND THEREOF APPLICATION | 2010 |
|
RU2565536C2 |
| METASTIN DERIVATIVES AND USE THEREOF | 2007 |
|
RU2454425C2 |
| NEW OCTAPEPTIDE COMPOUNDS AND THEIR THERAPEUTIC APPLICATION | 2011 |
|
RU2595525C2 |
